Related Experiment Video

Updated: Nov 20, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.3K

TLRs as a Promise Target Along With Immune Checkpoint Against Gastric Cancer

Lin Cui1, Xiuqing Wang1, Dekai Zhang2

  • 1Department of Gastroenterology and Hepatology, The Second Affiliated Hospital, Harbin Medical University, Harbin, China.

Frontiers in Cell and Developmental Biology
|January 20, 2021
PubMed

Insights

Toll-like receptors (TLRs) play a complex role in gastric cancer (GC) immunity. Targeting TLRs offers a promising avenue for novel immunotherapies to improve patient survival rates.

Area of Science:

  • Immunology
  • Oncology
  • Gastroenterology

Background:

  • Gastric cancer (GC) incidence is rising, particularly in Asia, with poor patient prognosis despite treatment advances.
  • Immune responses, both innate and adaptive, are crucial in cancer development and treatment.
  • Pattern recognition receptors (PRRs), including Toll-like receptors (TLRs), are key in initiating immune responses to pathogens and cellular damage.

Purpose of the Study:

  • To elucidate the intricate mechanisms of TLRs in gastric cancer immunity.
  • To review current progress in TLR-based therapeutic strategies and other immunotherapies for GC.
  • To highlight TLRs as potential targets for enhancing gastric cancer treatment outcomes.

Main Methods:

  • Review of existing literature on TLRs, tumor immunity, and gastric cancer.
  • Analysis of the role of PRRs, PAMPs, and DAMPs in the context of GC.
  • Synthesis of data on TLR agonists as therapeutic agents and adjuvants.

Main Results:

  • TLRs are implicated in the occurrence, progression, and treatment response of gastric cancer.
  • TLRs exhibit complex and varied functions within the heterogeneous landscape of GC.
  • TLR agonists demonstrate potential as standalone treatments or adjuncts to other immunotherapies.

Conclusions:

  • TLRs represent a significant and promising target for developing novel immunotherapies against gastric cancer.
  • Understanding TLR signaling pathways is critical for optimizing GC treatment strategies.
  • TLR-based approaches may offer a new paradigm for improving survival in gastric cancer patients.
Keywords:
agonistgastric cancerimmune checkpointimmunotherapytoll-like receptortumor immunity

More Related Videos

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)08:42

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)

Published on: June 27, 2025

1.3K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
866
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.4K